Sign in with your social account?

Alnylam Pharmaceuticals Inc.

Profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran for amyloidosis, Alnylam has partnered several pipeline candidates, including hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements.